OncoSil Medical Limited (ASX:OSL) Annual Report 2022



The latest annual report of OncoSil Medical Limited (OSL) was published on 30 Jun 2022. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - OSL Annual Results

Amounts in AUD

Total Revenue
$231.79K
Gross Profit
$1.07M
EBIT
$-5.36M
Net Tangible Assets
$4.82M
Net Income
$-10.73M
Capital Expenditures
-

OSL Income Statement 2022 Annual Report

As per the latest Income Statement of OSL, the Net revenue increased by $18.72K (9%) compared to the previous period. The operating income in 2022 increased by - (-). The net income as per the annual report was $-10.73M which decreased by $-293.18K (-3%) compared to previous year.

Income Statement Report (2022/2021)

2022 2021
Total Revenue $231.79K $213.07K
Gross Profit $1.07M $1.07M
Operating Income - -
Income Before Tax - -
Net Income $-10.73M $-10.43M

Balance Sheet - OSL 2022 Annual Report

Read further: OSL Balance Sheet Detailed Analysis

The latest balance sheet from annual result of OncoSil Medical Limited showed the company increased the cash on balance sheet by $0.00 (0%). The Net tangible assets of OSL on the balance sheet were at $4.82M which is $0.00 (0%) more than previous annual report. The total stockholder equity also increased by - (-) compared to previous reporting period.

Balance Sheet Statement Report (2022/2021)

2022 2021
Cash $2.85M $2.85M
Total Assets - -
Long Term Debt - -
Total Liabilities $42.47K $42.47K
Total Shareholder Equity - -
Net Tangible Assets $4.82M $4.82M

Cash Flow Statement - OSL 2022 Annual Report

The 2022 annual cash flow statement of OncoSil Medical Limited showed that the net income decreased by $-293.18K (-3%) compared to previous reporting period. Also the capital expenditure of OSL increased by - (-).

As of 2022, the total cash from investing activities was - and total cash from financing activities was -.

Cash Flow Statement Report (2022/2021)

2022 2021
Net Income $-10.73M $-10.43M
Capital Expenditures - -
Dividends Paid - -
Total Cash From From Investing Activities - -
Total Cash From From Financing Activities - -

OncoSil Medical Limited Annual Report History

Income Statement

Income Statement history of OncoSil Medical Limited (ASX:OSL)

30 Jun 2022 30 Jun 2021 30 Jun 2020 30 Jun 2019
Total Revenue $231.79K $213.07K $2.96M $0.00
Cost Of Revenue $0.00 $0.00 $0.00 $0.00
Gross Profit $0.00 $0.00 $0.00 $0.00
Research Development - - - -
Selling General Administrative - - - -
Non Recurring - - - -
Other Operating Expenses - - - -
Total Operating Expenses $0.00 $0.00 $0.00 $0.00
Operating Income - - - -
Total Other Income Expense Net - - - -
Ebit $0.00 $0.00 $0.00 $0.00
Interest Expense - - - -
Income Before Tax - - - -
Income Tax Expense $0.00 $0.00 $0.00 $0.00
Minority Interest - - - -
Net Income From Continuing Ops - - - -
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income $-10.73M $-10.43M $-4.26M $-8.57M
Net Income Applicable To Common Shares - - - -

Balance Sheet Statement

Balance Sheet Statement history of OncoSil Medical Limited (ASX:OSL)

30 Jun 2022 30 Jun 2021 30 Jun 2020 30 Jun 2019
Cash $2.85M $2.85M - -
Total Assets - - - -
Total Liab $42.47K $42.47K - -
Long Term Debt - - - -
Total Stockholder Equity - - - -
Net Tangible Assets $4.82M $4.82M - -

Cash Flow Statement

Cash Flow Statement history of OncoSil Medical Limited (ASX:OSL)

30 Jun 2022 30 Jun 2021 30 Jun 2020 30 Jun 2019
Net Income $-10.73M $-10.43M - -
Capital Expenditures - - - -
Dividends Paid - - - -
Total Cashflows From Investing Activities - - - -
Total Cash From Financing Activities - - - -